PMID- 38515845 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240323 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 15 DP - 2024 TI - Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on "time in range" in patients with type 2 diabetes. PG - 1370594 LID - 10.3389/fphar.2024.1370594 [doi] LID - 1370594 AB - Background: Diabetes affects millions of people worldwide annually, and several methods, including medications, are used for its management; glucagon-like peptide-1 receptor agonists (GLP-1RAs) are one such class of medications. The efficacy and safety of GLP-1RAs in treating type 2 diabetes mellitus (T2DM) have been assessed and have been shown to significantly improve time in range (TIR) in several clinical trials. However, presently, there is a lack of real-world evidence on the efficacy of GLP-1RAs in improving TIR. To address this, we investigated the effect of GLP-1RA-based treatment strategies on TIR among patients with T2DM in real-world clinical practice. Methods: This multicenter, retrospective, real-world study included patients with T2DM who had previously used a continuous glucose monitoring (CGM) system and received treatment with GLP-1RAs or oral antidiabetic drugs (OADs). Patients who received OADs served as controls and were matched in a 1:1 ratio to their GLP-1RA counterparts by propensity score matching. The primary endpoint was the TIR after 3-6 months of treatment. Results: According to propensity score matching, 202 patients were equally divided between the GLP-1RA and OAD groups. After 3-6 months of treatment, the TIR values for the GLP-1RA and OAD groups were 76.0% and 65.7%, respectively (p < 0.001). The GLP-1RA group displayed significantly lower time above range (TAR) and mean glucose values than the OAD group (p < 0.001). Subgroup analysis revealed that, compared with the administration of liraglutide, the administration of semaglutide and polyethylene glycol loxenatide (PEG-Loxe) significantly improved TIR over 3-6 months of treatment (p < 0.05). Conclusion: These real-world findings indicate that GLP-1RA-based treatment strategies could be superior to oral treatment strategies for improving TIR among patients with T2DM and that once-weekly GLP-1RA may be more effective than a once-daily GLP-1RA. Clinical trial registration: http://www.chinadrugtrials.org.cn/index.html, identifier number ChiCTR2300073697. CI - Copyright (c) 2024 Chen, Chen, Zhang, Zhu, Deng, Zuo, Hu, Zhao, Duan, Lin, Chen, Liang, Zheng, Khan and Hou. FAU - Chen, Yongru AU - Chen Y AD - The First Affiliated Hospital of Shantou University Medical College, Shantou, China. FAU - Chen, Jingxian AU - Chen J AD - School of Public Health, Shantou University, Shantou, China. AD - Shantou University Medical College, Shantou, China. FAU - Zhang, Shuo AU - Zhang S AD - The First Affiliated Hospital of Shantou University Medical College, Shantou, China. AD - Shantou University Medical College, Shantou, China. FAU - Zhu, Dan AU - Zhu D AD - Department of Endocrine and Metabolic Diseases, Longhu People's Hospital, Shantou, China. FAU - Deng, Feiying AU - Deng F AD - The First Affiliated Hospital of Shantou University Medical College, Shantou, China. AD - Shantou University Medical College, Shantou, China. FAU - Zuo, Rui AU - Zuo R AD - School of Public Health, Shantou University, Shantou, China. FAU - Hu, Yufei AU - Hu Y AD - School of Public Health, Shantou University, Shantou, China. FAU - Zhao, Yue AU - Zhao Y AD - School of Medicine, Tulane University, New Orleans, LA, United States. FAU - Duan, Yale AU - Duan Y AD - Department of Medical Affairs, Hanson (Shanghai) Health Technology Co, Ltd, Shanghai, China. FAU - Lin, Benwei AU - Lin B AD - School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, United Kingdom. FAU - Chen, Fengwu AU - Chen F AD - The First Affiliated Hospital of Shantou University Medical College, Shantou, China. FAU - Liang, Yun AU - Liang Y AD - Shantou University Medical College, Shantou, China. FAU - Zheng, Jiaxiong AU - Zheng J AD - School of Public Health, Shantou University, Shantou, China. FAU - Khan, Barkat Ali AU - Khan BA AD - Drug Delivery and Cosmetic Lab (DDCL), Gomal Center of Pharmaceutical Sciences, Faculty of Pharmacy, Gomal University, Dera Ismail Khan, Pakistan. FAU - Hou, Kaijian AU - Hou K AD - School of Public Health, Shantou University, Shantou, China. LA - eng PT - Journal Article DEP - 20240307 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC10955089 OTO - NOTNLM OT - continuous glucose monitoring OT - glucagon-like peptide-1 receptor agonists OT - oral antidiabetic drugs OT - time in range OT - type 2 diabetes COIS- Author YD is employed by Hanson (Shanghai) Health Technology Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/03/22 06:45 MHDA- 2024/03/22 06:46 PMCR- 2024/03/07 CRDT- 2024/03/22 04:01 PHST- 2024/01/15 00:00 [received] PHST- 2024/02/22 00:00 [accepted] PHST- 2024/03/22 06:46 [medline] PHST- 2024/03/22 06:45 [pubmed] PHST- 2024/03/22 04:01 [entrez] PHST- 2024/03/07 00:00 [pmc-release] AID - 1370594 [pii] AID - 10.3389/fphar.2024.1370594 [doi] PST - epublish SO - Front Pharmacol. 2024 Mar 7;15:1370594. doi: 10.3389/fphar.2024.1370594. eCollection 2024.